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SUMMARY
The NRL-PRL murine model, defined by mammary-
selective transgenic rat prolactin ligand rPrl expres-
sion, establishes spontaneous ER+mammary tumors
in nulliparous females, mimicking the association be-
tween elevated prolactin (PRL) and risk for develop-
ment of ER+ breast cancer in postmenopausal
women. Whole-genome and exome sequencing in a
discovery cohort (n = 5) of end-stage tumors revealed
canonical activating mutations and copy number am-
plifications of Kras. The frequent mutations in this
pathway were validated in an extension cohort, iden-
tifying activating Ras alterations in 79% of tumors (23
of 29). Transcriptome analyses over the course of
oncogenesis revealed marked alterations associated
with Ras activity in established tumors compared
with preneoplastic tissues; in cell-intrinsic processes
associated with mitosis, cell adhesion, and invasion;
as well as in the surrounding tumor environment.
These genomic analyses suggest that PRL induces
a selective bottleneck for spontaneous Ras-driven tu-
mors that may model a subset of aggressive clinical
ER+ breast cancers.
INTRODUCTION
Epidemiologic evidencehas linkedhigher levels of circulating pro-
lactin (PRL) with increased risk for estrogen receptor alpha (ER+)
breast cancers, particularly in postmenopausal women (Tikk
et al., 2014; Tworoger and Hankinson, 2008; Tworoger et al.,
2013). However, the role of PRL in tumor progression is more
controversial (Hachim et al., 2016; Shemanko, 2016; Tworoger
and Hankinson, 2008). Moreover, activation of STAT5A, the
downstream mediator of canonical PRL signals, is associated
with a better prognosis (Peck et al., 2012; Tworoger and Hankin-
son, 2008). To distinguish the contributions of PRL to breast can-
cer from its actions in pregnancy,we generated theNRL-PRLmu-
rine model, where transgenic rat PRL (rPRL) is secreted by
mammary epithelia to mimic the local production of PRL reported
in women (Marano and Ben-Jonathan, 2014; McHale et al., 2008;
O’Leary et al., 2015; Rose-Hellekant et al., 2003). In young adult
nulliparous NRL-PRL females, prior to evidence of detectable
mammary lesions, ductal epithelia proliferate more rapidly and
exhibit increased progenitor activity and Wnt signaling, resulting
in reduced maturation of luminal progenitors compared with
wild-type (WT) littermates (O’Leary et al., 2017; Rose-Hellekant
et al., 2003). With age, NRL-PRL females develop hyperplastic le-
sions that strongly express ER and progesterone receptor (PR)
and eventually develop histologically diverse and metastatic car-
cinomas (O’Leary et al., 2015; Rose-Hellekant et al., 2003). In
contrast to the preneoplastic lesions, established tumors express
variable ER and low PR, resembling the luminal B subtype of clin-
ical breast cancer (Arendt et al., 2011; O’Leary et al., 2015).
To understand the mechanisms that underlie the ability of
PRL to drive the development of cancers in this model, we
used comprehensive genomic analyses to identify genomic
alterations and patterns of gene expression associated with can-
cer progression. In a discovery set of five independent, histologi-
cally diverse carcinomas andmatched adjacent tumor-freemam-
mary glands from aged NRL-PRL females, we found that all
tumors contained somatic alterations in Kras, including canonical
activating mutations (i.e., G12, G13, and Q61) or amplifications
that resulted in elevated Ras pathway activation. Kras was not
altered in any preneoplastic mammary glands. Our findings
were validated in an extension set of 22 tumors and 4 cell lines
(derived from two additional tumors), demonstrating activating
Ras alterations in 79% of tumors. Ras activation was associated
with increased phosphorylation of ERK1/2 and transcripts for
Ras target genes and some pathway mediators, but variable rPrl
transgene expression and reduced canonical downstreammedi-
atorsofPRLsignaling. Thesefindingscoincidewith recent reports
that elevated Ras signaling drivesmany clinical luminal B cancers
and is associatedwith a poor prognosis (Olsen et al., 2017;Wright
et al., 2015). In contrast to Kras-activated tumors, preneoplastic
mammary glands maintained constitutive expression of rPrl and
displayed elevated transcripts for inflammatory cytokines.
Together, these data indicate that constitutive PRL signaling in
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mammary glands induces a pro-tumor environment, facilitating
Ras pathway activation and spontaneous tumorigenesis.
RESULTS
To understand the molecular events underlying development of
the prolactin-induced carcinomas in NRL-PRL females, we inter-
rogated a discovery set from 10 NRL-PRL nulliparous female
mice, consisting of five young adults and five aged tumor-
bearing mice. Mammary cell preparations (MCPs) were har-
vested from the caudal glands of NRL-PRL females (n = 5) at
12 weeks (young adults), prior to morphologic evidence of pa-
thology. Following the formation of spontaneous tumors at
15–20 months of age, three tissues from these mice were
collected: (1) end-stage mammary tumors, (2) adjacent non-tu-
mor mammary tissue (aged mammary glands [AMGs]), and (3)
matched tail tissue (Figure 1A; Table S1). Mammary glands
from 12-week-old mice contained primarily simple ductal struc-
tures and expressed ER and PR at levels similar to WT age-
matched females (Figure 2A). In contrast, mammary glands of
aged NRL-PRL females contained hyperplastic epithelial struc-
tures and expressed ER/PR similar to ductal structures of young
glands of either genotype (Figure 2B). The ER+ tumors that
develop in this model are histotypically diverse, including more
differentiated adenocarcinomas (such as T2 and T3) and less
differentiated spindle cell carcinomas (such as T1, T4, and T5).
These end-stage tumors expressed lower levels of PR than
structures in nondysplastic or hyperplastic AMGs (Figure 2B).
Genomic Characterization
Whole-genome sequencing (WGS) andwhole-exome sequencing
(WES) were performed on end-stage tumors andmatched tails for
A
B C
Figure 1. Sample Cohort Summary
(A) For our discovery set, mammary cell preparations (MCPs) were isolated from caudal glands of 12-week-old NRL-PRL females (MCPs A–E, n = 5). Nulliparous
mice with matched end-stage tumors (T) and adjacent aged mammary glands (AMGs) were collected following development of spontaneous ER+ tumors
(15–20 months; T1–T5, AMG1–AMG5, n = 5). All samples were examined by RNA-seq. Tumors and matched tail DNA samples underwent WGS and WES.
(B) In our extension set, we evaluated 22 additional tumors from NRL-PRL females (T6–T27) and 4 cell lines (derived from 2 independent tumors).
(C) Summary of samples interrogated in this study. The number of mice associated with each group or the sample identifiers are indicated in parentheses. *Four
cell lines were derived from 2 additional independent tumors (2 each).
See Table S1 for further details.
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mice within the discovery set (n = 5). Somatic variants were de-
tected by comparing tumors with matched tail sequencing data.
A range of 3–20 nonsilent mutations (median, 12) were identified
in each tumor (Figures 3A and S1; Table S2). Kras was the only
recurrently mutated gene in this cohort, with missense mutations
detected in 4 of 5 tumors. Activating mutations occurred at two
known hotspots (three G12D and one Q61L) and were present
among the highest fractions (13%–67%DNAvariant allele fraction
[VAF]) within tumors, suggesting their presence in the founding
clone of the tumors. Kras-activating mutations were confirmed
in the RNA of end-stage tumors (at 46%–75% VAF); however,
they were not present in RNA derived from adjacent AMG tissues.
The tumor without an activating mutation (T5) was assessed for
copynumber and structural variantsofKras, and a focal amplifica-
tion and structural variant were identified containing theKrasgene
locus. There were no large-scale copy number alterations, struc-
tural variants, or gene-gene fusions recurrently altered across
the discovery set outside of Kras (Figure S1).
Confirmation of Kras Activation in rPrl-Induced Tumors
We hypothesized that prolonged PRL exposure was creating a
selective bottleneck for activating Kras mutations in the NRL-
PRLmousemodel. To determine whether mutations at this locus
were consistent in a larger set of these tumors, Sanger
sequencing was performed on Kras exons 2 and 3 (containing
the G12, G13, and Q61 hotspot loci) in an extension set of 22 in-
dependent PRL-induced tumors (15 archival tumors [T6–T20]
and 7 fresh tumors with matched tails [T21–T27]) and 4 cell lines
derived from 2 additional PRL-induced tumors (Figure 1B; Table
S1). Hotspot mutations were identified in 14 tumors and all cell
lines in this set (Figure 3B; Table 1). Overall, the most common
alteration was Kras G12D (n = 9).
WES was performed on the eight tumors within the exten-
sion set that did not contain Kras-activating mutations in
exons 2 or 3. The mutational burden in these tumors ranged
from 0–12 (median 6). Other mutations were not identified in
Kras; however, there was a missense mutation in Nras in
one tumor (T21, A59D, 21.3% VAF; Table S2). The copy num-
ber landscape was evaluated for Kras copy number alter-
ations, as identified in T5 from the discovery set. Copy number
was evaluated by quantifying the depth of exome sequencing
and normalized per sample. A putative copy number increase
in Kras was identified in one other tumor (T23), with an average
copy number of 7.76 (Figure 3C). For reference, the average
copy number within the discovery set was 1.34, whereas T5
exhibited an average copy number of 29. Given that an
increased copy number is significantly associated with higher
Kras expression in T5, we hypothesized that copy number
alterations in sample T23 could affect transcript expression
(Figure 3D). Together, these data demonstrated that at least
23 of 29 (79%) independent spontaneous NRL-PRL tumors
developed alterations in Ras genes. We were unable to iden-
tify similar somatic alterations using WES in 6 tumors from
the extension set (T6, T7, T12, T13, T17, and T25). Five of
these tumors did not have matched normal tails available,
reducing confidence in somatic mutation calling and filtering.
Additional WGS of these tumors may provide further resolution
of the somatic landscape. We focused our subsequent
expression analysis on the discovery set, which, like the ma-
jority of the tumors, had Kras-activating alterations.
Analysis of Human Genomic Datasets for Ras Mutation
Recurrence
We queried previously reported clinical datasets to better under-
stand how the NRL-PRL mouse model can be used to compre-
hend ER+ human breast cancers. Consistent with the sponta-
neous tumors that arise in this model, amino acid G12 is the
most recurrently mutated position in KRAS (Figure 3B; Banerji
et al., 2012; Cancer Genome Atlas Network, 2012; Curtis et al.,
2012; Griffith et al., 2018; Lefebvre et al., 2016; Stephens et al.,
2012). This analysis was extended to include other RAS proteins
Figure 2. Histology of Sequenced Mammary Glands and Histologi-
cally Diverse Carcinomas
(A) Mammary glands of 12-week-old NRL-PRL females did not exhibit marked
morphological differences and did not express different levels of ER and PR
from wild-type (WT) age-matched females.
(B) Histology of tumors sequenced and characterized in the discovery set and
representative adjacent glands.
ER, estrogen receptor alpha; PR, progesterone receptor. Scale bars, 50 mm.
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and RasGAP tumor suppressors (KRAS,NRAS,HRAS,RASAL2,
and DAB2IP) because of recent evidence revealing that a high
proportion of luminal B ER+ breast cancers display elevated
Ras pathway activity as a result of attenuated expression or so-
matic loss of RasGAP proteins (Olsen et al., 2017; Wright et al.,
2015). Thus, although the frequency of KRAS alterations is low
in human breast cancers (0%–6.94%), the Ras pathway is
altered in 3.8%–22.9% of patients with ER+ breast tumors (Fig-
ure S2; Table S3).
Ras Pathway Activation Differentiates Expression in
Tumors and Dysplastic Glands
Gene expression was evaluated across the samples from the
discovery set, including five nondysplastic MCPs from young
Figure 3. Summary of Kras Modifications in NRL-PRL Tumors
(A) The mutation frequency ranged from 3–20 nonsynonymous coding mutations across the five tumors in the discovery set (median, 12; top bar chart). The
mutation burden (mutations per megabase) is shown. The only recurrently mutated gene in our cohort was Kras (top row of the bottom plot). The waterfall plot
indicates the types of mutations detected in the remainder of the cohort (as detailed in the legend below C).
(B) Schematic of all mutations, comparing the prevalence of Krasmissense mutations in tumors in NRL-PRLmice (n = 29; 20 contained Krasmissense mutations)
with KRAS missense mutations in human breast cancer: The Cancer Genome Atlas [TCGA], n = 825; METABRIC, n = 2,056; Lefebvre et al. (2016), n = 216;
Stephens et al. (2012), n = 100; Banerji et al. (2012), n = 103; Griffith et al. (2018), n = 1,038.
(C) Left: Normalized depth of sequencing (coverage normalized by respective sample total sequencing depth) over the exons spanning the Kras gene locus (in
320- to 920-bpwindows) of all tumor and normal samples. Tumor samples are not normalized with respect tomatched normal data becausematched normal tails
were not available for all mice. Right: the average depth of sequencing (all windows) within the Kras locus is indicated on a log2 scale. Amplifications detected in
T5 and T23 are labeled.
(D) RNA-seq data were available for T1–T5 (discovery set). The copy number (right panel, C) of Kras is plotted along the x axis, and the gene expression of Kras (in
fragments per kilobase transcript per millionmapped reads [FPKM]; quantified by Cufflinks, see STARMethods) is indicated on the y axis. Note, two points nearly
overlap. Refer to Figures S1 and S2 and Table S3 for further details.
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females and dysplastic AMGs and end-stage tumors from five
aged tumor-bearing mice. Unsupervised approaches indicated
clustering based upon sample source, where end-stage tumors
behaved more similar to other tumors than their matched adja-
cent AMGs (Figure 4A). To understand the varied expression pat-
terns across sample types, we first quantified rPrl transgene
expression in each sample. rPrl expression was maintained in
both nondysplastic MCPs and dysplastic AMGs but varied in tu-
mors (Figure 4B). Lower-grade, more differentiated tumors
(T2 and T3) contained relatively high levels of transgene tran-
scripts, whereas high-grade spindle cell carcinomas (T1, T4,
and T5) expressed very low levels of rPrlmRNA. This association
suggests that rPrl transgene expression may influence tumor
phenotype but is not required for tumor maintenance.
To determine the downstream effects specific to Kras activa-
tion, supervised differential expression analysis was performed,
comparing matched tumors with adjacent AMGs. There were 41
genes that were differentially expressed between these two tis-
sue types (q < 0.001) that were also annotated as part of the
Kyoto Encyclopedia of Genes and Genomes (KEGG) Ras
pathway (mmu04014). This included upregulation of Mapk1,
Map2k1, and Src mRNAs in end-stage tumors (Figure 4C), indi-
cating higher levels of transcripts for mediators of the Ras
pathway in Kras-driven tumors than in AMGs. Consistently, tu-
mors, but not adjacent AMGs, displayed strong phosphorylation
of ERK1/2 and AKT by immunohistochemistry (Figure 4D).
In normal mammary function, most PRL signals are mediated
by the JAK2/STAT5A pathway (Oakes et al., 2008). Activation of
this signaling cascade results in phosphorylation and dimeriza-
tion of STAT5A, which then translocates to the nucleus to regu-
late transcription (Hammarén et al., 2018). Interestingly, Stat5a
mRNA was significantly reduced in end-stage tumors compared
with AMGs (Wald test, q = 1.54e5; Figure 4C), particularly in
poorly differentiated tumors T1, T4, and T5. Non-tumor mam-
mary structures adjacent to the tumors also displayed strong nu-
clear STAT5A staining (Figure 4D), suggesting that the constitu-
tive rPrl expression seen consistently across AMGs was
activating this signaling cascade.
Tumorigenic Processes and the Microenvironment
Differ across Stages of Disease Progression
Subsequent gene set enrichment and pathway analyses using
the RNA sequencing (RNA-seq) data from the discovery set re-
vealed multiple changes with respect to disease progression.
Upregulation of tumorigenic processes, including cell cycle
regulation and cell adhesion, were associated with Ras pathway
activation in end-stage tumors (Tables S4 and S5; Figures 5A
and 5B). Chromosome organization and chromatin structure,
mitotic nuclear division, as well as cadherin and proteins
involved in cell adhesion and adherens junctions were signifi-
cantly upregulated in tumors compared with AMGs or MCPs
(Figure 5B). This is consistent with increased mitotic and
invasive properties of cancer cells. AMGs displayed increased
expression of genes related to fatty acid metabolism and adipo-
genesis relative to MCPs and tumors (p < 0.01; Figures 5A and
5B), reflecting the higher proportion of adipocytes in these
preparations.
Compared with MCPs, both AMGs and tumors showed signif-
icantly lower expression of processes related to immune activa-
tion, including leukocyte cell-cell adhesion and aggregation, and
T cell activation (q < 0.01; Tables S4 and S5; Figures 5A and 5B).
These observations led us to hypothesize that the immune
microenvironment differed across stages of disease. Markers
of hematopoietic and immune cell lineages were significantly
downregulated in tumors compared with preneoplastic cells,
including Ptprc, Cd8a, Cd4, Tra, Trb, Cd40, and Cd19 mRNAs
(p < 0.001), suggesting that tumors have reduced immune infil-
trate, specifically those responsible for adaptive immune recog-
nition and rejection (Table S4). We therefore interrogated the
RNA-seq data to predict the relative proportions of infiltrating im-
mune cell subpopulations using deconvolution approaches to
further resolve the immune landscape across the discovery set
(Chen et al., 2018). All samples displayed a mixture of immune
cell subpopulations, and each tumor showed considerable di-
versity in the predicted proportions of these immune cell types
(Figure 5C). Macrophages represented the predominant immune
cell population across all samples (Figure 5C); however, these
algorithmic approaches only determined the relative proportion
of immune cell subpopulations without quantifying the absolute
levels of immune infiltrate in each sample.
To confirm findings and evaluate trends in the RNA-seq
data, we examined select transcripts by RT-PCR in the discovery
set. In addition, MCPs were generated from WT 12-week-old
females (WT MCPs) and from aged NRL-PRL females (aged
mammary cell preparations [AMCPs]), enabling us to assess pro-
cesses associated with preneoplastic changes in similar mam-
mary cell preparations. Lipid metabolic enzymes (Acadm and
FasnmRNAs) were significantly upregulated in AMGs compared






Kras amplification 2 2




Kras G13 1 1
G13A 1 1
Kras Q61 2 5 6
Q61H 2 1 2
Q61L 1 1
Q61R 3 3
Nras A59 1 1
A59D 1 1
Number of mutated samples (tumors) 4 (2)a 21 25 (23)
Number of total samples (tumors) 4 (2)a 27 31 (29)
aFour cell lines were derived from 2 additional independent tumors
(2 each). In total, 29 independent tumors were evaluated; 23 (79%) had
detectable Ras pathway mutations.
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with AMCPs, confirming that the AMG preparations of tissue
adjacent to tumors were enriched with adipocytes (Figure 6A).
To further elucidate the stages of PRL-induced pathogenesis,
hormone receptors and signaling pathways were interrogated.
Although transcripts for ERa (Esr1) were not altered across
samples, Pgr transcripts fell markedly with disease progression
(Figure 6B), confirming detected protein expression (Figure 2).
Acquisition of somatic alterations in Kras in tumors was asso-
ciated with loss of Stat5a mRNA (Figure 6C), consistent with the
reduction in nuclear STAT5A protein (Figures 4C and 4D).
Increased Notch activity, indicated by Hes1 transcripts, and
Ccne1 mRNA in both AMCPs and tumors were consistent with
increased proliferation of preneoplastic epithelial populations
and tumors in NRL-PRL females (Zender et al., 2013). However,
Ccnd1, Padi4, and Hmga2 transcripts were upregulated only
in tumors, indicating high proliferation and chromatin remodel-
ing, well-recognized cell-autonomous effects of elevated Ras
activity; the dramatic rise in CCND1 protein expression in tumors
was confirmed using immunohistochemistry (IHC) (Figures 6D
and 6G, i). Unsurprisingly, tumors also showed striking eleva-
tions in transcripts associated with invasion and interaction
with the extracellular matrix (Itgb4 and Mmp9) (Figure 6E).
Interrogation of cytokines and immune mediators revealed
significant differences between tumors and preneoplastic mam-
mary tissue (Figure 6F). Hyperplastic AMCPs, prior to Kras alter-
ations, displayed elevated levels of Nfkb1, Csf1, Csf2, Ifng, and
Tgfb1 mRNAs, encoding inflammatory cytokines. However,
most of these transcripts, along with Icam1mRNA, were precip-
itously lower in established tumors, depicting an immunosup-
pressed environment. This was reflected in the low numbers of
CD8+ intratumoral lymphocytes (Figure 6G, ii), confirming the
RNA-seq data (Tables S4 and S5; Figure 5C). In contrast, intra-
tumoral F4/80+ myeloid cells were plentiful (Figure 6G, iii; as
predicted in Figure 5C). Tgfb1 remained elevated, and Arg1
and Nos2 transcripts were increased in tumors, consistent with
shifts in activation of resident myeloid populations, including
macrophages and myeloid-derived suppressor cells (Sica and
Bronte, 2007). Together, these data support marked changes
in the immune microenvironment in PRL-induced mammary
pathogenesis.
DISCUSSION
Increased local exposure to PRL in the NRL-PRLmodel results in
spontaneous diverse ER+ mammary cancers after a long la-
tency, mimicking clinical luminal B, ER+ cancers in postmeno-
pausal women. Here we demonstrated that Ras pathway activa-
tion in this model, particularly through recurrent somatic
alterations in Kras, follows constitutive PRL signaling. Elevated
Ras activity was associated with reduced activity in the canoni-
cal PRL-JAK2/STAT5A signaling cascade despite continued
transgene expression in some tumors. Transcriptome analyses
over the course of oncogenesis revealed marked alterations
associated with Ras activity in established tumors in cell-intrinsic
processes associated with mitosis, cell adhesion, and invasion
as well as in the tumor microenvironment, including immune
activity.
Mirroring the connection to human disease (Tikk et al., 2014;
Tworoger and Hankinson, 2008; Tworoger et al., 2013), PRL
has been observed to promote mammary carcinogenesis in
multiple genetically engineered mouse models (Arendt and




Figure 4. Constitutive Prolactin Signaling
Induces a Selective Bottleneck for Ras
Pathway Activation
(A) Unsupervised principal-component analysis
was performed across nondysplastic MCPs
(n = 5), AMGs (n = 5), and end-stage spontaneous
ER+ tumors (n = 5) from the discovery set. The
color indicates the sample type.
(B) Kallisto was used to quantify transgene
expression in transcripts per million (TPM). Pseu-
doalignment of RNA reads was performed against
the annotated mouse transcriptome and rPrl
(ENSRNOT00000023412.4).
(C) Heatmap displaying expression of canonical
downstreammediators of prolactin signaling (Jak2
and Stat5a) and Ras pathwaymediators (Mapk1/3,
Akt1/2/3, Src,Map2k1, and Kras). Fill indicates the
expression level in FPKM for AMG and tumor
samples from the discovery set.
(D) Immunohistochemical staining for STAT5A,
pERK1/2, and pAKT in two representative tumors
of different histotypes with adjacent glands (left
and right). Tumor regions are indicated by T in the
image, and arrows point to adjacent AMGs. Scale
bars, 50 mm.
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in combination with other oncogenes (Arendt et al., 2006, 2009;
O’Leary et al., 2014), and, conversely, its absence increases tu-
mor latency in combination with viral oncogenes (Oakes et al.,
2008; Vomachka et al., 2000). Interestingly, BALB/c mice im-
planted with pituitary isografts, which elevate circulating PRL,
develop mutagen-induced mammary tumors that also exhibit
mutations inKras (Guzman et al., 1992). Furthermore, expression
of transgenic Kras G12V in beta lactoglobulin-expressing mam-
mary cells during lactation (driven in part by high PRL) results in
ER+ tumors in C57BL/6 mice (Andò et al., 2017). The link be-
tween PRL and development of Ras-driven mammary tumors
in these distinct mouse models in different genetic backgrounds




Figure 5. Tumorigenic Processes Differ across Stages of Disease Progression
(A) Supervised differential expression analysis was performed on all comparisons of nondysplastic MCPs (n = 5), AMGs, and end-stage tumors (n = 5) from the
discovery set. Genes that were significantly upregulated (p < 0.0001) in either tumors (compared with AMGs and MCPs) or glands (compared with tumors and
MCPs) that were also annotated within significantly upregulated GO annotations (p < 0.001) are shown in the heatmap (n = 229). Fill indicates the gene-median
centered expression value, calculated with respect to the entire discovery set. GO annotations were grouped into cellular processes, and genes corresponding to
each annotation are noted in the side color bar (STAR Methods).
(B) A representative set of differentially expressed GO processes, categorized as ‘‘Cell Cycle’’ and ‘‘Immune Processes’’ in (A), are displayed based on their
q value. Following eachGOprocess, the number of genes included in the annotation is indicated. Comparisons are summarized as those that were upregulated in
either MCPs or tumors compared with the other sample types.
(C) seq-ImmuCC was used to predict the relative proportions of immune cell populations (y axis) in MCPs, AMGs, and end-stage tumors from the discovery set.
Samples are ordered by identifier (MCP A–E, AMG 1–5, and Tumors 1–5).
Refer to Tables S4 and S5 for further details.





Figure 6. Validation of RNA-Seq Findings
(A–F) RT-PCR was used to evaluate transcripts associated with cellular processes altered with oncogenesis (identified in Figure 5) across samples in the dis-
covery set (MCP, AMG, and tumor; indicated by y) as well as aged mammary cell preparations from NRL-PRL females (AMCP). These include fatty acid
metabolism (A), hormone receptors (B), signaling pathways (C), cell cycle (D), cell adhesion (E), and immune processes (F). MCPs were also isolated from wild-
type young adults (WTMCP) (n = 4–5). Data are represented asmean ± SEM. Significant differences were determined by one-way ANOVA, followed by the Tukey
post-test. *p < 0.05, **p < 0.01, and ***p < 0.001.
(G) Immunohistochemistry demonstrating higher levels of CCND1 expression in tumors compared with preneoplastic tissue (i), low levels of CD8+ intratumoral
lymphocytes compared with mammary lymphoid tissue (inset, ii), and F4/80+ myeloid cells within tumors and stroma and surrounding preneoplastic structures
(inset, iii). Scale bars, 50 mm.
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Germline ablation of Stat1 in 129/SvEv mice results in mam-
mary tumors that acquire a truncating mutation in Prlr, resulting
in its constitutive activation (Griffith et al., 2016). The well-differ-
entiated tumors in Stat1/ mice are characterized by strong
STAT5 phosphorylation (Chan et al., 2014), similar to tumors
that develop in response to transgenic Stat5a (Iavnilovitch
et al., 2004). However, in NRL-PRL females, the robust STAT5
activation in preneoplastic mammary structures was markedly
absent in established tumors, associated with reduced Stat5a
mRNA and acquisition of Ras mutations, demonstrating a transi-
tion from the JAK2/STAT5 axis to the Ras signaling pathway.
Consistently, tumors that arise in NRL-PRL females lose depen-
dence on JAK2 signaling with disease progression (Sakamoto
et al., 2010), whereas mammary tumors in Stat1-deficient mice
remain dependent on JAK2 (Chan et al., 2014). Together, these
data are congruent with a model whereby JAK2/STAT5A signals
promote early tumorigenesis, but their ongoing activity supports
well-differentiated, less aggressive luminal cancers that are
more likely to respond to anti-estrogen therapies (Peck et al.,
2012; Rädler et al., 2017).
Although all tumors in the NRL-PRL discovery set developed
alterations in Ras family members, any ongoing role of the
JAK2/STAT5 pathway and PRL-initiated signals appeared to
differ across individual tumors. In the discovery set, the more
differentiated adenocarcinomas (T2 and T3) maintained
transgenic rPrl expression and showed slightly higher Stat5a
mRNA than the less differentiated spindle cell carcinomas
(T1, T4, and T5). Continued STAT5A signals may promote
cell adhesion and other differentiated characteristics in these
tumors (Nouhi et al., 2006; Sultan et al., 2005), despite the overall
reduction of Stat5a transcripts compared with preneoplastic
cells. PRL is able to initiate a diverse spectrum of signals apart
from JAK2/STAT5, including activation of Src and downstream
pathways and crosstalk with the Ras cascade itself (Barcus
et al., 2013; Erwin et al., 1995; Martı́n-Pérez et al., 2015). These
observations likely account for the controversy surrounding the
role of PRL signals in clinical disease (Hachim et al., 2016;
Shemanko, 2016).
Analysis of differentially expressed genes and associated
processes with disease progression revealed complex alter-
ations in cell signaling, the cytokine milieu, and the immune
microenvironment early in PRL-driven pathogenesis. Together
with PRL-augmented mammary epithelial progenitor cell sub-
populations (O’Leary et al., 2017), our findings predict elevated
inflammatory cytokines prior to acquisition of Ras pathway
mutations that may contribute to tumorigenesis. End-stage
tumors with genetic alterations in Kras exhibited marked modu-
lation of the immune response, including reduced expression of
inflammatory cytokines and increased markers of activated
myeloid cells. These findings are consistent with the literature
describing immune evasion by Kras activation bymultiple mech-
anisms, including reduced expression of tumor antigens and
promotion of recruitment and differentiation of immune popula-
tions that inhibit anti-tumor immune activity (Cullis et al., 2018;
Dias Carvalho et al., 2018). Future studies will elucidate interac-
tions between preneoplastic or malignant epithelial cells and the
immune microenvironment through stages of PRL-induced
pathogenesis.
The low rate of somatic mutations, reduced levels of tran-
scripts encoding markers of many immune cell lineages, and
low numbers of CD8+ infiltrating lymphocytes in NRL-PRL tu-
mors mimic the relative immune silence of clinical luminal breast
cancers (Dieci et al., 2016; Luen et al., 2016; Vonderheide et al.,
2017). Recent studies have revealed that a high proportion of
luminal B ER+ breast cancers display elevated Ras pathway ac-
tivity as a result of reduced expression or somatic loss of Ras-
GAP tumor suppressors (Griffith et al., 2018; Olsen et al., 2017;
Wright et al., 2015). Thus, although the frequency of KRAS alter-
ations is low, collectively, RAS proteins and RasGAP tumor sup-
pressors (KRAS, NRAS, HRAS, RASAL2, and DAB2IP) are
altered in a significant subset of ER+ breast tumors in publicly
available datasets (Figure S2; Banerji et al., 2012; Cancer
Genome Atlas Network, 2012; Curtis et al., 2012; Griffith et al.,
2018; Lefebvre et al., 2016; Stephens et al., 2012). RAS itself
has been an elusive therapeutic target (McCormick, 2015; Tran
et al., 2016). However, targeting RAS-modulated immune regu-
lators (Candido et al., 2018; Mitchem et al., 2013) may intercept
T cell-suppressive signaling by pro-tumor myeloid populations.
This approach may facilitate responses to T cell-directed thera-
pies, such as the recent exciting anecdotal report of T cell trans-
fer in metastatic breast cancer (Zacharakis et al., 2018).
For many years, it was questioned whether mouse models of
mammary cancer could be estrogen responsive and model clin-
ical luminal breast cancers. However, the ER+ cancers that
develop in the NRL-PRL model, like the Stat1/ and Kras
(G12V) models (Andò et al., 2017; Chan et al., 2012), demon-
strate that the tools available for murine systems can be valuable
to study ER+ breast cancer. Even in PRL-induced tumors that
have lost dependence on estrogen for growth, ER-mediated
signals continue to modulate cell phenotype and cancer stem
cell activity (Shea et al., 2018). These preclinical immunocompe-
tent models of estrogen-responsive mammary tumors can pro-
vide insight into the biological behavior of these cancers,
including metastasis, tumor cell plasticity and cancer stem cell
activity, therapeutic responsiveness, and patterns of resistance.
We would like to emphasize the critical need for comprehensive
genomic studies in relevant experimental models to understand
the similarities and differences from human disease and optimize
the translational efficacy of thesemodels. Without such genomic
profiling, many models are being used and interpreted without
understanding the full set of molecular alterations that drive
and define the model. Our studies of tumorigenesis in the NRL-
PRL model describe the ability of constitutive rPrl expression
to create a pro-tumor mammary environment converging into a
selective bottleneck conducive for Ras pathway activation,
which initiates aggressive tumor growth, invasion, and immuno-
suppression of the tumor microenvironment, features shared
with a subset of clinical ER+ breast cancers.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Cyclin D1 Biocare Medical Cat# CP236B
Estrogen receptor Santa Cruz Biotechnology Cat# SC-542; RRID:AB_631470
pAKT S473 Cell Signaling Technologies Cat# 3787; RRID:AB_331170
pERK1/2 Cell Signaling Technologies Cat# 9101; RRID:AB_331646
STAT5A Santa Cruz Biotechnology Cat# SC-1081; RRID:AB_632448
CD8 ThermoFisher Cat# 14008185; RRID:AB_467088
F4/80 Biolegend Cat# 123102; AB_893506
Progesterone Receptor Dako Cat# A0098; RRID:AB_2315192
Biological Samples




Blood & Cell Culture DNA Mini Kit QIAGEN 13323
TruSeq PCR free WGS library preparation kit Illumina 20015962
RNEasy Midi Kit QIAGEN 75142
TruSeq Stranded Total RNA library preparation kit Illumina 20020596
Phusion Hot Start Flex DNA polymerase New England Biolabs M0535
QIAquick PCR Purification Kit QIAGEN 28104
M-MLV reverse transcriptase Promega M1705
SYBR Green ThermoFisher 4309155
Deposited Data




Ensembl reference transcriptome v84 Ensembl ftp://ftp.ensembl.org/pub/release-84/gtf/mus_
musculus/
Mouse Genomes Project v142 Keane et al., 2011 ftp://ftp-mouse.sanger.ac.uk/REL-1505-SNPs_Indels/
Human breast cancer sequencing dataset Banerji et al., 2012 http://www.cbioportal.org/
Human breast cancer sequencing dataset Cancer Genome Atlas
Network, 2012
http://www.cbioportal.org/
Human breast cancer sequencing dataset Curtis et al., 2012 http://www.cbioportal.org/
Human breast cancer sequencing dataset Lefebvre et al., 2016 http://www.cbioportal.org/
Human breast cancer sequencing dataset Stephens et al., 2012 http://www.cbioportal.org/
Human breast cancer sequencing dataset Griffith et al., 2018 phs001234.v1.p1
Raw and analyzed data This Paper SRP189110
Experimental Models: Organisms/Strains
Mouse: NRL-PRL [lines 1647-13, TgN(Nrl-Prl)23EPS;
1655-8, TgN(Nrl-Prl)24EPS]
Rose-Hellekant et al., 2003 N/A
Oligonucleotides
Primers for Real Time PCR, see Table S6 This Paper N/A
Primers for Sanger Sequencing, see Table S6 This Paper N/A
Software and Algorithms
Codon Code Aligner [v 7.0.1] CodonCode Corporation https://www.codoncode.com/aligner/
Genome Modeling System Griffith et al., 2015 https://github.com/genome/gms
BWA-MEM v0.7.10 Li, 2013 https://github.com/lh3/bwa
SAMBLASTER v0.1.22 Faust and Hall, 2014 https://github.com/GregoryFaust/samblaster
(Continued on next page)
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Obi
Griffith (obigriffith@wustl.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
NRL-PRL mice [lines 1647-13, TgN(Nrl-Prl)23EPS; 1655-8, TgN(Nrl-Prl)24EPS] were generated and maintained in the FVB/N strain
background (O’Leary et al., 2015; Rose-Hellekant et al., 2003). All tumors in the Discovery Set were TgN(Nrl-Prl)23EPS; the Extension
Set included archived tumors of both lines. Mice were housed and handled in accordance with the Guide for Care and Use of Lab-
oratory Animals in AAALAC-accredited facilities, and all procedures were approved by the University of Wisconsin-Madison Animal
Care and Use Committee.
Sample Acquisition
We examined changes with age and pathogenesis in heterozygotic nulliparous females. Mammary epithelial cells were isolated
from 12 week old animals, prior to evidence of morphological abnormalities. Other animals were aged until the primary
mammary tumors were 1.5 cm in diameter (end stage), when the tumors, adjacent mammary glands, and tails were collected
and flash frozen for subsequent analyses. For the Extension Set, an additional 22 tumors and 2 pairs of cell lines derived from
2 independent tumors were examined. These additional tumors included 7 freshly isolated tumors and matched tails, and
15 archived tumors were equally distributed among the glandular, papillary, and spindle cell carcinoma histotypes. All tumors
analyzed developed in the cranial glands, reflecting the predominance of this site in this and many other transgenic mammary
cancer models.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
SomaticSniper v1.0.4 Larson et al., 2012 http://gmt.genome.wustl.edu/packages/somatic-
sniper/
VarScan2 v2.3.6 Koboldt et al., 2012 http://varscan.sourceforge.net/
Strelka v1.0.11 Saunders et al., 2012 https://github.com/Illumina/strelka
Mutect v1.1.4 Cibulskis et al., 2013 https://software.broadinstitute.org/cancer/cga/mutect
GATK Somatic Indel Detector v5336 McKenna et al., 2010 https://software.broadinstitute.org/gatk/
Samtools r982 Li et al., 2009 http://samtools.sourceforge.net/
CopyCat v0.1 N/A https://github.com/chrisamiller/copyCat
Manta Chen et al., 2016 https://github.com/Illumina/manta
Integrate Zhang et al., 2016 https://sourceforge.net/projects/integrate-fusion/
cBioPortal Gao et al., 2013 http://www.cbioportal.org
Kallisto Zerbino et al., 2018 https://pachterlab.github.io/kallisto/
TopHat Trapnell et al., 2009 https://github.com/infphilo/tophat
Cufflinks Trapnell et al., 2010 https://github.com/cole-trapnell-lab/cufflinks
HTSeq-count Anders and Huber,
2010
https://htseq.readthedocs.io/en/release_0.11.1/
DESeq2 Love et al., 2014 https://bioconductor.org/packages/release/bioc/html/
DESeq2.html
Gene set enrichment analysis (fgsea) Sergushichev, 2016 https://bioconductor.org/packages/release/bioc/html/
fgsea.html
Ggplot2 Wickham, 2009 https://ggplot2.tidyverse.org/
GenVisR Skidmore et al., 2016 https://bioconductor.org/packages/release/bioc/html/
GenVisR.html
Seq-ImmuCC Chen et al., 2018 http://218.4.234.74:3200/immune/
Other
Manual review standard operating procedures Barnell et al., 2018 N/A
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METHOD DETAILS
Morphological and Immunohistochemical Analyses
Samples were collected and fixed overnight in 10% neutral buffered formalin and processed into 5micron sections. Mammary struc-
tures were assessed in hematoxylin and eosin (H&E) stained tissue sections, and protein expression was visualized by immunohis-
tochemistry as previously described (Arendt et al., 2011) using antibodies against the following antigens: Cyclin D1, CP236B, Biocare
Medical, (1:200); ER, #SC-542, Santa Cruz Biotechnology (1:500); PR, A0098, Dako (1:500); pAKTS473, #3787, Cell Signaling Tech-
nologies (1:50); pERK1/2, #9101, Cell Signaling Technologies (1:400); STAT5A, #SC-1081, Santa Cruz Biotechnology (1:5000). For
CD8 and F4/80, frozen sections were stained. Tissues were embedded in OCT and frozen in a dry ice/methanol bath. Seven micron
sections were cut, fixed with acetone at 20C for 20 min, blocked with 5% normal goat serum and incubated overnight with either
anti-CD8, Clone 53-6.7, Invitrogen (1:1000) or anti-F4/80, Clone BM8, Biolegend, (1:250). Slides were then processed in the same
manner as for the paraffin sections.
Library Construction and Sequencing Strategy
Genomic DNA was isolated using the QIAGEN Blood & Cell Culture DNA Mini Kit (#13323; Hilden, Germany). Whole genome
sequencing (WGS) libraries for matched tumor and normal tail samples (n = 5) were prepared using the Illumina TruSeq PCR free
kit with dual indexed adaptors.WGS libraries were pooled and sequenced across 1 flow cell (8 lanes) on the Illumina HiSeq X platform
with paired 2 3 150 bp reads with median 33.35X coverage (27.18-37.52X). Whole exome sequencing (WES) libraries for matched
tumor and normal tail samples were pooled and sequenced on 1 lane of an Illumina HiSeq 4000 with paired 2 3 150 bp reads with
median 37.99X coverage (10.39-85.45X). Total RNAwas isolated using theQIAGENRNeasyMidi Kit (#75142; Hilden, Germany). RNA
sequencing (RNAseq) libraries were prepared using the Illumina TruSeq stranded total RNA kit. Libraries were pooled and sequenced
across 4 lanes of a HiSeq 4000 with 2 3 150 bp reads with median 60,072,344 total reads (43,482,392-100,068,565 total reads).
Sanger Validation Sequencing
For the Extension Set and positive controls from the Discovery Set, the regions surrounding Kras hotspots G12/G13 and Q61
were amplified from 5ng of genomic DNA, using Phusion Hot Start Flex DNA polymerase (#M0535; New England Biolabs), and
primers which tagged products with M13F(21) (forward strand) and M13R (reverse strand) sequences (see Table S6 for Primer
Sequences). PCR products were purified using the QIAquick PCR Purification Kit (#28104; QIAGEN), and sent to GeneWiz (South
Plainfield, NJ) for Sanger Sequencing. Traces were manually assessed for variants within G12, G13, and Q61 using the CodonCode
Aligner software (version 7.0.1; CodonCode Corporation).
DNA sequencing and analysis
TheGenomeModeling System (GMS) was used for all analysis, including the somatic variant detection andRNA-seq analysis (Griffith
et al., 2015). WGS and WES data were processed through SpeedSeq v0.1.0 (Chiang et al., 2015; Faust and Hall, 2014), which aligns
reads by BWA-MEM v0.7.10 (Li, 2013) to the mouse reference genome (NCBI build 38, GRCm38) and marks duplicates using
SAMBLASTER v0.1.22 (Faust and Hall, 2014). Matched (normal) tail samples were analyzed for all 5 tumors in the Discovery Set
and 3 tumors in the Extension Set which did not exhibit Kras G12, G13, or Q61 mutations. Somatic events were identified by
individually comparing tumor DNA to matched tail (normal) DNA. Single nucleotide variants (SNVs) were detected by the union of
SomaticSniper v1.0.4 (Larson et al., 2012), VarScan2 v2.3.6 (Koboldt et al., 2012), Strelka v1.0.11 (Saunders et al., 2012), andMutect
v1.1.4 (Cibulskis et al., 2013). Small insertions and deletions (indels) were detected by taking the union of GATK Somatic Indel
Detector (v5336) (McKenna et al., 2010), Varscan2, and Strelka. 5 tumors from the Extension Set which did not exhibit Kras G12,
G13, or Q61 mutations did not have DNA from matched normal tail samples (T6, 7, 12, 13, and 17). For these tumors, SNV/indels
were detected by comparing the aligned tumorWESdata to themouse reference genomeGRCm38 using Varscan 2 (v2.3.6) (Koboldt
et al., 2012).
SNV/indels were filtered using Samtools r982 (Li et al., 2009) ([mpileup -BuDS] filtered by var-filter-snv v1 then false-positive-vcf v1)
and annotated by the GMS transcript variant annotator against Ensembl v84. Mutations were filtered to those annotated as nonsy-
nonymous Tier 1 mutations within the protein-coding regions, meeting the following thresholds: minimum 5 reads supporting the
variant, minimum 5% variant allele frequency, minimum 20X coverage of the corresponding genomic position in the tumor sample,
and minimum 20X coverage of the corresponding genomic position in the normal tail sample (if available). The 8 tail samples were
used as a ‘panel of normal’ samples in order to remove common nucleotide polymorphisms and artifacts with the following require-
ments: SNVswith aminimum2.5%VAFwith 20X coverage detected in at least 2 (25%) of the normal samples or Indels withminimum
2% VAF with 2X coverage detected in at least 2 (25%) of the normal samples. Following this filtering strategy, false positives were
manually removed, as previously described (Barnell et al., 2018).
All variants were further filtered by removing those identified in normal mice by the Mouse Genomes Project (v142) (Keane et al.,
2011). There were no remaining variants detected in T23, likely indicating that this tumor had low tumor cellularity, making it difficult to
differentiate sequencing artifacts from variants detected. There were five tumors (T6, T7, T12, T13, T17) without matched normal tail
samples. Recurrent mutations that were identified only in these unmatched tumors were removed as likely germline variants. Further-
more, mutations in olfactory receptor and uncharacterized cDNA regions (Olfr and Rik genes) were removed.
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Copy number variants, including Kras amplifications, were identified using CopyCat v0.1 [https://github.com/chrisamiller/
copyCat], comparing matched tumor and normal tail samples, if available. In tumors with no matched normal samples, copy number
alterations were detected by normalizing the depth of sequencing within each sample over the exons spanning the Kras gene locus
(in 320-920 bp windows). While there were no variants detected in T23, there was increased normalized coverage over the Kras gene
locus indicating a possible copy number amplification. Structural variants were predicted using Manta onWGS andWES data (Chen
et al., 2016), and intergenic fusions were detected using Integrate (Zhang et al., 2016).
Publicly Available Datasets
Clinical and mutational data from five public datasets (Banerji et al., 2012; Cancer Genome Atlas Network, 2012; Curtis et al., 2012;
Lefebvre et al., 2016; Stephens et al., 2012) were obtained through cBioPortal (Gao et al., 2013). Samples were filtered to those an-
notated as ‘Breast Cancer’ (removing ‘Breast Sarcoma’). Patients were annotated as ‘ER+ or HR+/HER2-’ in Figure S2 based upon
the ‘ER Status’ and ‘HR+/HER2-’ columns in the clinical annotations. These datasets were specifically queried for mutations and
copy number alterations in KRAS, NRAS, HRAS, DAB2IP, and RASAL2. The Griffith dataset (Griffith et al., 2018) contained only
HR+/HER2- breast cancers, and was only assessed for KRAS mutations (the other four genes were not evaluated in this targeted
gene panel study).
rPrl Expression Analysis
A kallisto index was built to incorporate the annotated Ensembl mouse transcriptome (v92) and the full rPrl transcript
(ENSRNOT00000023412.4) (Zerbino et al., 2018). RNaseq reads were pseudoaligned to this kallisto index to quantify read abun-
dance and expression (TPM) of rPrl.
RNA Expression Analysis
RNaseq reads were aligned to the mouse reference genome (NCBI build 38, GRCm38) using TopHat (Trapnell et al., 2009). Cufflinks
(Trapnell et al., 2010) and HTSeq-count (Anders and Huber, 2010) were used to quantify gene and transcript expression, and differ-
ential expression analysis was performed using the DESeq2 R package (Love et al., 2014). Gene Set Enrichment Analysis was per-
formed using the fgsea R package (Sergushichev, 2016). The GAGER packagewas used for pathway analysis, and data visualization
was performed using the ggplot2 R package (Wickham, 2009) and GenVisR (Skidmore et al., 2016). Immune infiltrate was assessed
by seq-ImmuCC using the Illumina RNaseq platform and the SVRmethod (Chen et al., 2018). Immune populations were summarized
as relative frequencies (the default output of the program).
RT-PCR
Total RNA was isolated from samples in the Discovery Set (MCPs, AMGs, tumors), WT age-matched (12-14 week) MCPs, and non-
tumor mammary cells from aged (15-16 month) mice isolated using the MCP procedure, using the RNeasy Midi Kit (#75142;
QIAGEN). cDNA was synthesized from 1 mg of RNA using M-MLV reverse transcriptase (#M1705; Promega) and random hexamers.
Real time PCR was performed using SYBR Green (#4309155; ThermoFisher) on the Applied Biosystems 7300 platform as described
(Arendt et al., 2011) using the primer sequences in Table S6. Transcripts of interest were normalized to 18S RNA, and fold changes
calculated using the DDCt method.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis
Gene expression differences and statistics were summarized by the results of supervised comparisons in DESeq2. Specifically,
p values were calculated by Negative Binomial generalized linear model fitting and Wald statistics, and adjusted p values (q values)
were calculated by the Benjamini Hochberg method. Immune populations were compared using Mann-Whitney tests between
groups.
DATA AND CODE AVAILABILITY
The reference-aligned whole genome, exome, and RNA sequencing data and sample details for 36 tumor and non-tumor mouse tis-
sues have been submitted to NCBI SRA study SRP189110, BioProject PRJNA489661.
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Supplemental Figures 
Figure S1. Somatic discovery in the Discovery and Extension 
Sets. Related to Figure 3. 
A.​ Representative screenshot from the Integrated Genome Viewer (IGV) displaying a ​Kras​ G12 
mutation in the Discovery Set, present in tumor whole genome, whole exome, and RNA 
sequencing reads (WGS, WES, RNA), but not in the normal WGS and WES, nor RNA from 
matched aged mammary glands (AMGs). ​B.​ Representative Sanger traces from the Extension 
Set, including mutations detected in ​Kras​ at either G12, G13, or Q61. ​C.​ Copy number 
landscape of the Discovery Set. Fill color represents the relative copy number of the genomic 
region. 
 
Figure S2. Ras pathway alterations in human breast cancer 
datasets. Related to Figure 3 and Table S3. 
A.​ Summary of samples assessed from publicly available human breast cancer datasets. 
Samples are differentiated as either ‘ER+ or HR+/HER2-’ or ‘ER- or Not Defined’ (indicated by 
color), as described in cBioPortal ​(Banerji et al., 2012; Cancer Genome Atlas Network, 2012; 
Curtis et al., 2012; Griffith et al., 2018; Lefebvre et al., 2016; Stephens et al., 2012)​. ​B.​ Somatic 
alterations detected in samples from A, categorized by gene (color) and ER status. Alterations 
are summarized as copy number amplifications (AMP), homozygous deletion (HOMDEL), or 
point mutations (MUT). ​C-F. ​Schematics Lolliplots depicting specific point mutations identified in 




Table S3. Ras pathway alterations in human breast cancer 
datasets. Related to Figures 3 and S2. 
The number of somatic alterations - including mutations, amplifications, and deletions - detected 
across public datasets. Values indicate the number of patients with alterations in each 
corresponding gene (row), or the total number of patients with mutations in any gene (bottom 
row; percent is calculated as the number of patients with alterations within the associated 
subtype). “NA” indicates that the gene was not evaluated in the corresponding gene (The Griffith 
et al. dataset did not evaluate mutations in genes other than ​KRAS​). * Patients may have 
alterations in more than one gene. 
 
 METABRIC (n=2,506) 
Griffith et al. 
(n=1,038) TCGA (n=825) 
Lefebvre et al. 
(n=216) 
Banerji et al. 
(n=103) 
Stephens et al. 
(n=100) 






















KRAS 22 44 1 7 9 8 7 0 0 1 0 
HRAS 16 6 NA 3 2 7 4 0 0 1 0 
NRAS 15 4 NA 2 4 1 0 0 0 0 0 
DAB2IP 9 9 NA 7 3 1 2 1 0 1 0 
RASAL2 374 68 NA 19 6 12 3 1 1 0 0 
Total Patients 
with Alterations* 
(% of subtype) 
417 
(22.9%) 
121 
(17.7%) 
1 
(0.1%) 
37 
(6.2%) 
24 
(10.7%) 
26 
(18.2%) 
14 
(19.2%) 
2 
(4.5%) 
1 
(1.7%) 
3 
(3.8%) 
0 
(0%) 
 
